Bezuclastinib/Sunitinib Combination Under Evaluation in Adva

The TKI bezuclastinib plus standard-of-care sunitinib may become the new second-line standard treatment for patients with gastrointestinal stromal tumor that has progressed on imatinib.

Related Keywords

London , City Of , United Kingdom , Houston , Texas , United States , Robin Jones , Neeta Somaiah , Department Of Sarcoma Medical Oncology , University Of Texas Md Anderson Cancer Center , Division Of Cancer Medicine , Sarcoma Unit , Royal Marsden , Sarcoma Medical Oncology , Cancer Medicine , Cancer Center , Bezuclastinib , Sunitinib , Gastrointestinal Stromal Tumor , Peak Trial , Nct05208047 ,